Rheumatology International

, 29:297

A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China

  • Dawei Hu
  • Chunde Bao
  • Shunle Chen
  • Jieruo Gu
  • Zhanguo Li
  • Lingyun Sun
  • Xinghai Han
  • Liqing Ni
Original Article

Abstract

The objective of this study is to evaluate the efficacy and safety of rhTNFR:Fc: a recombinant tumor necrosis factor receptor:Fc fusion protein compared with methotrexate (MTX) in patients with rheumatoid arthritis in China. We treated 238 patients with active rheumatoid arthritis with either twice weekly subcutaneous injection rhTNFR:Fc (25 mg) or weekly oral MTX (mean 15 mg per week) for 24 weeks (registration number: 2003L01264). Clinical responses were defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatology (ACR-N). As compared with MTX-treated patients, more patients who received rhTNFR:Fc had ACR20 improvement in disease activity during the first 2 weeks (P < 0.05). Similarly, more patients treated with rhTNFR:Fc having ACR20, ACR50, ACR70 improvement in disease activity during 8 weeks (P < 0.05). At the end of 12-week treatment, patients received rhTNFR:Fc also had significant improvement at ACR20 (P < 0.05). Compared with oral MTX, patients received rhTNFR:Fc also had significant improvement at ACR70 at the end of 24 weeks treatment (P < 0.05). In conclusion, compared with oral MTX subcutaneous injection, rhTNFR:Fc acted more rapidly to release symptoms and signs of active RA in Chinese patients, and well tolerated in patients with rheumatoid arthritis in China.

Keywords

Tumor necrosis factor Recombinant fusion protein Methotrexate Rheumatoid arthritis 

References

  1. 1.
    Feldmann M, Brennan FM, Maini RN (1996) The role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14:397–440CrossRefGoogle Scholar
  2. 2.
    Braunstein J, Allendorf J, Reister M et al (1994) How are soluble forms of ICAM-1 (sCD54) and LFA-3 (sCD58) generated? Immunobiology 340:253–259Google Scholar
  3. 3.
    Wooley PH, Dutcher J, Widmer MB et al (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602PubMedGoogle Scholar
  4. 4.
    Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Eng J Med 337:141–147PubMedCrossRefGoogle Scholar
  5. 5.
    American College of Rheumatology (1996) Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713Google Scholar
  6. 6.
    Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 6:727CrossRefGoogle Scholar
  7. 7.
    Felson DT, Anderson JJ, Boers M et al (1995) Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735PubMedCrossRefGoogle Scholar
  8. 8.
    Saag KG, Koehnke R, Caldwell JR et al (1994) Low dose long term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–116PubMedCrossRefGoogle Scholar
  9. 9.
    Simm LS (1993) Nonsteroidal anti-inflammatory drug toxicity. Curr Opin Rheumatol 5:265CrossRefGoogle Scholar
  10. 10.
    Cash JM, Klippel JH (1994) Second-line drug therapy for rheumatoid arthritis. N Engl J Med 330:1368PubMedCrossRefGoogle Scholar
  11. 11.
    Grom A, Murray KF, Luyrink L et al (1996) Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 39:1703PubMedCrossRefGoogle Scholar
  12. 12.
    Firestein GS, Zvaifler NJ (1997) Anticytokine therapy in rheumatoid arthritis. N Engl J Med 337:195–197PubMedCrossRefGoogle Scholar
  13. 13.
    Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Eng J Med 343:1586–1593PubMedCrossRefGoogle Scholar
  14. 14.
    Moreland LW, Cohen SB, Baumgartner SW et al (2001) Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28:1238–1244PubMedGoogle Scholar
  15. 15.
    Fusconi M, Vannini A, Dall’aglio AC et al (2007) Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Rheumatol Int 28(1):47–49PubMedCrossRefGoogle Scholar
  16. 16.
    Weinblatt ME, Kremer JM, Bankhurst A et al (1999) A trial of etanercept: a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. New Eng J Med 340:253–259PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Dawei Hu
    • 1
  • Chunde Bao
    • 1
  • Shunle Chen
    • 1
  • Jieruo Gu
    • 2
  • Zhanguo Li
    • 3
  • Lingyun Sun
    • 4
  • Xinghai Han
    • 5
  • Liqing Ni
    • 6
  1. 1.Department of RheumatologyRenji Hospital, Shanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Department of RheumatologyThird Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  3. 3.Department of RheumatologyPeople’s Hospital, Peking UniversityBeijingChina
  4. 4.Department of RheumatologyNanjing Drum Tower Hospital, Medical School of Nanjing UniversityNanjingChina
  5. 5.Department of RheumatologyChanghai Hospital, The Second Military Medical UniversityShanghaiChina
  6. 6.Department of RheumatologyGuanghua HospitalShanghaiChina

Personalised recommendations